Skip to main content
SpringerLink
Log in

Primäre Psychose und Typ-2-Diabetes

Bedeutung von Metformin

Primary psychosis and type 2 diabetes

Importance of metformin

  • Kasuistiken
  • Published:
Der Diabetologe Aims and scope

Zusammenfassung

Es wird über eine 37-jährige Patientin berichtet, die unter der antipsychotischen Therapie, bestehend aus Olanzapin und Risperidon, eine starke Gewichtszunahme (BMI [Body-Mass-Index] 38,9 kg/m2) und im Verlauf einen Diabetes mellitus Typ 2 entwickelte. Nach Einstellung auf Metformin 2 g/Tag kam es im Verlauf zu einer Besserung der BZ-Werte und Gewichtsabnahme. In Anbetracht der aktuellen Studienlage und hieraus entwickelten Leitlinien stellt sich die Frage, ob ein Behandlungsversuch mit Metformin im Vorfeld zu einer signifikanten Gewichtsreduktion führt und somit eine präventive Maßnahme in Bezug auf die Entstehung einer diabetischen Stoffwechsellage darstellt.

Abstract

This article presents the case of a 37-year-old woman who developed an ongoing weight gain (body mass index [BMI] 38.9 kg/m2) and subsequently type 2 diabetes during antipsychotic treatment with olanzapine and risperidone. After receiving metformin (2 gram/day), the blood sugar levels improved and the patient was able to start losing weight within weeks. In regards to the actual studies and guidelines, we discuss whether metformin could have been given at an earlier time during treatment to reduce the patient’s weight and possibly prevent the development of type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72(12):1172–1181

    Article  Google Scholar 

  2. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, Collantoni E, Pigato G, Favaro A, Monaco F, Kohler C, Vancampfort D, Ward PB, Gaughran F, Carvalho AF, Stubbs B (2017) Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16(2):163–180

    Article  Google Scholar 

  3. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and metaanalysis. World Psychiatry 14(3):339–347

    Article  Google Scholar 

  4. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B (2016) Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 15(2):166–174

    Article  Google Scholar 

  5. Müller MJ, Benkert O (2017) Antipsychotika. In: Benkert O, Hippius H (Hrsg) Kompendium der Psychiatrischen Pharmakotherapie, Bd. 11. Springer, Berlin, Heidelberg, S 269–488

    Chapter  Google Scholar 

  6. Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261–269

    Article  Google Scholar 

  7. Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Arroyo MB, Kirkpatrick B (2017) Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res 179:57–63

    Article  Google Scholar 

  8. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10(1):52–77

    Article  Google Scholar 

  9. DGPPN e. V. (2019) S3-Leitlinie Schizophrenie. Langfassung, 2019, Version 1.0, zuletzt geändert am 15. März 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html

  10. WHO (2018) Management of physical health conditions in adults with severe mental disorders

    Google Scholar 

  11. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24(6):412–424

    Article  Google Scholar 

  12. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and 286 atypical antipsychotic drugs. Neuropsychopharmacology 28(3):519–526

    Article  CAS  Google Scholar 

  13. Bora E, Akdede BB, Alptekin K (2017) The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med 47(6):1030–1040

    Article  CAS  Google Scholar 

  14. Musil R, Obermeier M, Russ P, Hamerle M (2015) Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 14(1):73–96

    Article  CAS  Google Scholar 

  15. Lipkovich I, Jacobson JG, Caldwell C, Hoffmann VP, Kryzhanovskaya L, Beasley CM (2009) Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull 42(4):23–39

    PubMed  Google Scholar 

  16. Haddad P (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19(6 Suppl):16–27

    Article  Google Scholar 

  17. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962

    Article  CAS  Google Scholar 

  18. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31–41

    Article  CAS  Google Scholar 

  19. NICE (2014) NICE clinical guideline 178—Psychosis and schizophrenia in adults: treatment and management

    Google Scholar 

  20. SIGN (2013) Management of schizophrenia. A national clinical guideline. SIGN 131

    Google Scholar 

  21. Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, Correll CU (2016) Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 134(5):385–398

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vitos Klinik Eichberg, Kloster-Eberbach-Str. 4, 65346, Eltville, Deutschland

    Svenja Davis-Glurich, Bettina Haas, Karin Thume &  Dieter F. Braus

Authors
  1. Svenja Davis-Glurich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bettina Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Thume
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dieter F. Braus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Svenja Davis-Glurich.

Ethics declarations

Interessenkonflikt

D.F. Braus hat in den letzten Jahren über dessen Arbeitgeber produktneutrale Vorträge gehalten für Med-update, streamed-up, Janssen, Lilly, TAD, Takeda, Medice, Bayer, Lundbeck, Pfizer, Recordati, Sanofi, Sunovion, Amgen, Berlin-Chemie, MSD Sharp & Dohme, Servier. S. Davis-Glurich, B. Haas und K. Thume geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis-Glurich, S., Haas, B., Thume, K. et al. Primäre Psychose und Typ-2-Diabetes. Diabetologe 17, 739–743 (2021). https://doi.org/10.1007/s11428-021-00799-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-021-00799-9

Schlüsselwörter

Keywords

Search

Navigation